Skip to content

Comparison of the Efficacy of Vonoprazan–Doxycycline Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Infection in Elderly Patients: A 14-Day, Prospective, Multicenter, Open-Label, Randomized, Non-Inferiority Study

Comparison of the Efficacy of Vonoprazan–Doxycycline Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Infection in Elderly Patients: A 14-Day, Prospective, Multicenter, Open-Label, Randomized, Non-Inferiority Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125925
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-03
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori Infection

Interventions

Sponsors

Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 70 Years

Inclusion criteria

Inclusion criteria: Study participants must meet all of the following criteria to be eligible for inclusion in this study: 1.Elderly individuals aged 60-70 years; 2.Diagnosed with active H. pylori infection based on a positive result from any of the following tests: 13C or 14C urea breath test, rapid urease test, stool antigen test, or histological examination; 3.Conscious and mentally competent study participants who are legally and independently capable of understanding and signing the study informed consent form.

Exclusion criteria

Exclusion criteria: Study participants who meet any of the following criteria will be excluded from the study: 1.Known or previously documented history of hypersensitivity to any component of the investigational drug regimens; 2.Use of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CABs) within 2 weeks prior to screening; 3.Use of bismuth agents or any antibiotics (including traditional Chinese medicine components with antimicrobial properties) within 4 weeks prior to screening; 4.Presence of acute upper gastrointestinal bleeding within 1 week; 5.History of gastrectomy; 6.Co-morbid malignant tumors, severe renal impairment (glomerular filtration rate < 30 mL/min/1.73m^2), severe hepatic impairment (Child-Pugh class C), or other severe systemic diseases; 7.Other conditions determined by the investigator to be unsuitable for study participation, such as major medical diseases or psychiatric disorders that impede the implementation or completion of the protocol treatment and/or interfere with follow-up.

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication rate;

Secondary

MeasureTime frame
Medication adherence of study participants;

Countries

China

Contacts

Public ContactXiaowei Liu;Yu Peng

Xiangya Hospital, Central South University

pengyu918@csu.edu.cn+86 139 7489 9436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026